CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 36% versus third quarter of 2025 to approximately $710 million   Half of CARTITUDE-2 Cohort A patients remained alive and progression-free without further anti-myeloma treatment five years after a single CARVYKTI ®

CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 50% versus second quarter of 2025 to approximately $657 million Expanded CARVYKTI ® availability to 348 global sites and 19 global markets with the launch of Ireland Achieved first clinical proof-of-concept for LB2501, an

CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 62% versus first quarter of 2025 to approximately $597 million CARVYKTI ® now available across 18 global markets, following recent launches in Italy, Poland, the Czech Republic, and Australia Advanced early-stage cell

CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $555 million and $1.9 billion for the fourth quarter and full year 2025, respectively Surpassed milestone of more than 10,000 patients treated with CARVYKTI ® CARVYKTI now available across 294 sites worldwide;